Postpartum Depression Drugs Market Growth, Size, Trends Analysis- By Type, By Treatment, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

Postpartum Depression Drugs Market Introduction and Overview

As reported by SPER Market Research in their analysis "Global Postpartum Depression Drugs Market Growth, Size, Trends Analysis - By Type, By Treatment, By End User - Regional Outlook, Competitive Strategies, and Segment Forecast to 2033," the global postpartum depression drugs market is projected to reach $2,150.99 million by 2033, with an anticipated compound annual growth rate (CAGR) of 9.88%.

A medical disorder known as postpartum depression (PPD) can strike during pregnancy or in the first year following childbirth. Another name for this illness is peripartum depression. It is linked to persistent feelings of melancholy, worry, and exhaustion that persist for a considerable amount of time following childbirth. Postpartum depression is a common issue, impacting approximately 10% to 15% of women globally. Counselling and medicines can be used to treat this medical problem.

Impact of COVID-19: Covid-19 has a tremendous impact on the postpartum medication industry. Since the beginning of 2020, the Covid-19 epidemic has altered the healthcare system and the lifestyles of people all around the planet. People were confined to their homes for months and experienced an increase in mental health issues. The rise in mental health concerns and illnesses has raised the demand for antidepressants. Furthermore, data indicates that childbearing mothers were significantly impacted by the lockdowns and closures.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Type, By Treatment, By End User.

Regions covered

North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Companies Covered

Pfizer Inc, Sage Therapeutics, Inc, Bausch Health Companies Inc, Eli Lilly, Aurobindo Pharma, Lupin, Sun Pharmaceutical Industries Ltd, SHIONOGI & Co., Ltd, Cipla Inc, Teva Pharmaceutical Industries Ltd.

Postpartum Depression Drugs Market Segmentation:

By Type: Based on the Type, Global Postpartum Depression Drugs Market is segmented as; Postpartum Anxiety, Postpartum Post-Traumatic Stress Disorder, Postpartum Panic Disorder, Postpartum Psychosis, and Others.

By Treatment: Based on the Treatment, Global Postpartum Depression Drugs Market is segmented as; Psychotherapy, Supplements and Others.

By End User: Based on the End User, Global Postpartum Depression Drugs Market is segmented as; Hospitals and Clinics, Specialty Centers, and Others.

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Product Code: PHAR2418

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Postpartum Depression Drugs Market.

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Postpartum Depression Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Postpartum Depression Drugs Market

7. Global Postpartum Depression Drugs Market, By Type (USD Million) 2020-2033

7.1. Global Postpartum Depression Drugs Market Size, Share and Forecast, By Type, 2020-2026
7.2. Global Postpartum Depression Drugs Market Size, Share and Forecast, By Type, 2027-2033
7.3. Postpartum Anxiety
7.4. Postpartum Post-Traumatic Stress Disorder
7.5. Postpartum Panic Disorder
7.6. Postpartum Psychosis
7.7. Others

8. Global Postpartum Depression Drugs Market, By Treatment (USD Million) 2020-2033

8.1. Global Postpartum Depression Drugs Market Size, Share and Forecast, By Treatment, 2020-2026
8.2. Global Postpartum Depression Drugs Market Size, Share and Forecast, By Treatment, 2027-2033
8.3. Psychotherapy
8.4. Supplements
8.5. Others

9. Global Postpartum Depression Drugs Market, By End User (USD Million) 2020-2033

9.1. Global Postpartum Depression Drugs Market Size, Share and Forecast, By End User, 2020-2026
9.2. Global Postpartum Depression Drugs Market Size, Share and Forecast, By End User, 2027-2033
9.3. Hospitals and Clinics
9.4. Specialty Centers
9.5. Others

10. Global Postpartum Depression Drugs Market Forecast, 2020-2033 (USD Million)

10.1. Global Postpartum Depression Drugs Market Size and Market Share

11. Global Postpartum Depression Drugs Market, By Region, 2020-2033 (USD Million)

11.1. Global Postpartum Depression Drugs Market Size and Market Share By Region (2020-2026)
11.2. Global Postpartum Depression Drugs Market Size and Market Share By Region (2027-2033)
11.3. Asia-Pacific
- 11.3.1. Australia
- 11.3.2. China
- 11.3.3. India
- 11.3.4. Japan
- 11.3.5. South Korea
- 11.3.6. Rest of Asia-Pacific
11.4. Europe
- 11.4.1. France
- 11.4.2. Germany
- 11.4.3. Italy
- 11.4.4. Spain
- 11.4.5. United Kingdom
- 11.4.6. Rest of Europe
11.5. Middle East and Africa
- 11.5.1. Kingdom of Saudi Arabia
- 11.5.2. United Arab Emirates
- 11.5.3. Qatar
- 11.5.4. South Africa
- 11.5.5. Egypt
- 11.5.6. Morocco
- 11.5.7. Nigeria
- 11.5.8. Rest of Middle-East and Africa
11.6. North America
- 11.6.1. Canada
- 11.6.2. Mexico
- 11.6.3. United States
11.7. Latin America
- 11.7.1. Argentina
- 11.7.2. Brazil
- 11.7.3. Rest of Latin America

12. Company Profile

12.1. Pfizer Inc
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Sage Therapeutics, Inc
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. Bausch Health Companies Inc
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. Eli Lilly
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. Aurobindo Pharma
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Lupin
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. Sun Pharmaceutical Industries Ltd
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. SHIONOGI & Co., Ltd
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Cipla Inc
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Teva Pharmaceutical Industries Ltd
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Others